Equity · Healthcare
TXG
NASDAQ10x Genomics (TXG)
The line runs 58.45 USD on 11 August through 59.32 USD on 6 November, on a scale from 40 to 100. Days the market did not trade hold the previous close, flat.
- Market cap
- 7.7B USD
- Revenue, year to Dec 2025
- 642.8M USD
- EPS, diluted, year to Dec 2025
- −0.35 USD
- 52-week range
- 12 USD – 98 USD
- Avg volume
- 263.7K
- Mentions, 30 days
- 3
as of Nov 6, 2026
Have 10x Genomics (TXG) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, 10x Genomics insiders reported 12 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 24 Nov 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 22 Sep 2026
Buys 0Sells 12Net sold $12.24MOther filings 2
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 22 Sep 2026 | Saxonov SergeChief Executive Officer | Sell | 25,000 | 2.0M USD |
| 22 Sep 2026 | SULIMAN SHEHNAAZDirector | Sell | 5,723 | 465K USD |
| 09 Sep 2026 | Taich AdamChief Financial Officer | Sell | 46,388 | 3.0M USD |
| 03 Sep 2026 | STUELPNAGEL JOHN RDirector | Sell | 20,000 | 1.2M USD |
| 26 Aug 2026 | Saxonov SergeChief Executive Officer | Sell | 10,486 | 668K USD |
| 24 Aug 2026 | SULIMAN SHEHNAAZDirector | Sell | 2,207 | 140K USD |
| 24 Aug 2026 | Hindson Benjamin J.See Remarks | Sell | 13,818 | 871K USD |
| 24 Aug 2026 | Taich AdamChief Financial Officer | Sell | 17,166 | 1.1M USD |
| 24 Aug 2026 | Saxonov SergeChief Executive Officer | Sell | 18,545 | 1.2M USD |
| 14 Aug 2026 | Teichmann Sarah A.Director | Sell | 2,273 | 130K USD |
| 13 Aug 2026 | Teichmann Sarah A.Director | Sell | 5,278 | 302K USD |
| 11 Aug 2026 | STUELPNAGEL JOHN RDirector | Sell | 20,000 | 1.2M USD |
| Sold | 12 open-market sales | 186,884 | $12.24M |
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Sep 2026 | Saxonov SergeChief Executive Officer | Gift | 100 | |
| 20 Aug 2026 | Saxonov SergeChief Executive Officer | Gift | 4,000 |
Which funds hold 10x Genomics (TXG)?
10 of the 45 institutional funds we track reported a 10x Genomics position for the quarter ended 30 Jun 2026 — a combined 701.4M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| ARK Investment Management | Held (±25%) | 10,003,057 | 383.5M USD | −14.6% |
| Citadel Advisors | Added | 2,779,213 | 106.6M USD | +273.7% |
| AQR Capital Management | Held (±25%) | 2,026,464 | 74.7M USD | −20.2% |
| Point72 Asset Management | New position | 1,852,776 | 71.0M USD | |
| Renaissance Technologies | Held (±25%) | 802,039 | 30.8M USD | −20.5% |
| Duquesne Family Office | New position | 403,100 | 15.5M USD | |
| D. E. Shaw & Co. | Added | 233,069 | 8.9M USD | +240.0% |
| Two Sigma Investments | Trimmed | 141,776 | 5.4M USD | −64.8% |
| Millennium Management | Trimmed | 116,833 | 4.5M USD | −94.4% |
| Bridgewater Associates | Trimmed | 13,375 | 513K USD | −61.9% |
What has been filed or recorded for 10x Genomics (TXG)?
The filings we hold for 10x Genomics, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 65 shares | 5K USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 135 shares | 10K USD notional · <0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 90 shares | 7K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.15 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.1B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 838.0M USD | at period end |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 29 shares | 3K USD notional · <0.001% of shares out |
| 28 Sep 2026 | Fails to deliver | Shares failed to deliver | 19 shares | 2K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.14 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.10 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.35 USD | |
| 31 Dec 2025 | Financials | Revenue | 642.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −43.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.35 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.22 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.28 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.28 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.52 USD |
What is Reddit saying about 10x Genomics (TXG)?
Reddit mentioned TXG 3 times in the 30 days to 9 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 33% read bullish, 0% bearish and 67% neither. Reddit data updated 9 November 2026.
30-day window, Method
Mentions, 30 days 3Communities 2
How do Reddit mentions of 10x Genomics (TXG) compare with its price?
Share ↗
Where 10x Genomics (TXG) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 67% | 2 | +0.04 |
| r/stocks | 33% | 1 | +0.09 |
10x Genomics (TXG): frequently asked questions
What did 10x Genomics shares close at?
10x Genomics closed at 59.32 USD on 6 Nov 2026, up 2.33% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is 10x Genomics’ market cap?
10x Genomics is worth 7.7B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is 10x Genomics’ revenue?
10x Genomics reported revenue of 642.8M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have 10x Genomics insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, 10x Genomics insiders reported 12 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 24 Nov 2025, show no open-market purchase. A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own 10x Genomics?
10 of the 45 funds we track reported a 10x Genomics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were ARK Investment Management, Citadel Advisors and AQR Capital Management. See Funds
When did 10x Genomics last report earnings?
10x Genomics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.15 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about 10x Genomics?
10x Genomics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 3 times over the trailing 30 days. Of the 3 mentions scored for sentiment, 33% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings